Holen Sie sich die Stockscreener-App
36.11
2.62%
-0.97
Handel nachbörslich:
35.86
-0.25
-0.69%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt HROW?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$37.08
Offen:
$37.2
24-Stunden-Volumen:
488.24K
Relative Volume:
1.11
Marktkapitalisierung:
$1.32B
Einnahmen:
$154.15M
Nettoeinkommen (Verlust:
$-33.58M
KGV:
-37.61
EPS:
-0.96
Netto-Cashflow:
$-20.74M
1W Leistung:
+5.06%
1M Leistung:
+17.78%
6M Leistung:
+4.52%
1J Leistung:
+42.84%
1-Tages-Spanne:
$35.27
$37.59
1-Wochen-Bereich:
$33.33
$38.09
52-Wochen-Spanne:
$20.85
$59.23
Harrow Inc Stock (HROW) Company Profile
Firmenname
Harrow Inc
Sektor
Telefon
615.733.4731
Adresse
1A BURTON HILLS BLVD, NASHVILLE, CA
Vergleichen Sie HROW mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
36.11 | 1.26B | 154.15M | -33.58M | -20.74M | -0.96 |
|
ZTS
Zoetis Inc
|
151.19 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.55 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.65 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.29 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
297.89 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-12 | Eingeleitet | BTIG Research | Buy |
| 2025-06-10 | Eingeleitet | William Blair | Outperform |
| 2025-02-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-04 | Bestätigt | B. Riley Securities | Buy |
| 2024-04-11 | Eingeleitet | Craig Hallum | Buy |
| 2022-09-08 | Fortgesetzt | B. Riley Securities | Buy |
| 2021-10-14 | Fortgesetzt | B. Riley Securities | Buy |
| 2021-09-24 | Eingeleitet | Aegis Capital | Buy |
| 2021-07-02 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Harrow Inc Aktie (HROW) Neueste Nachrichten
Harrow Inc. Stock Analysis and ForecastBreakneck growth rates - jammulinksnews.com
What drives Harrow Inc. stock priceHigh-octane financial growth - jammulinksnews.com
Is Harrow Inc. a good long term investmentRapid capital growth - jammulinksnews.com
What analysts say about Harrow Inc. stockDynamic capital growth - jammulinksnews.com
Harrow, Inc. (HROW): A Bull Case Theory - Insider Monkey
Harrow jumps as Cantor initiates with Bullish view on conservative outlook - MSN
HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm - ETX View
Ladenburg Thalmann & Co. Keeps Their Buy Rating on Harrow Health (HROW) - The Globe and Mail
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc. – HROW - FinancialContent
Harrow purchases US commercialization rights to Samsung Bioepis' biosimilar portfolio - Eyes On Eyecare
Samsung Bioepis Partners with Harrow to Expand US Ophthalmology Market - Asia Business Outlook
Harrow's Strategic Positioning in the $9B Ophthalmology Biosimilars Market: Unlocking Value Through Biosimilar Commercialization and Medicare Savings - AInvest
Samsung Bioepis signs U.S. partnership for ophthalmology biosimilar sales - Yonhap News Agency
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Harrow, Inc.HROW - cnhinews.com
Harrow Enters Into Commercialization Agreement With Samsung Bioepis For Ophthalmology Biosimilars Portfolio In The United States - TradingView
Harrow Enters into Commercialization Agreement with Samsung Bioe - GuruFocus
Harrow acquires exclusive US rights to Samsung Bioepis eye drugs - Investing.com Australia
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States - Business Wire
Harrow Secures Landmark Deal for First FDA-Approved Eye Disease Biosimilars from Samsung Bioepis - Stock Titan
Q2 Earnings Estimate for Harrow Issued By William Blair - Defense World
(HROW) Trading Report - news.stocktradersdaily.com
FY2026 Earnings Estimate for Harrow Issued By William Blair - Defense World
Why Harrow Inc. stock attracts strong analyst attentionBreakout Level Watch - Newser
How Harrow Inc. stock performs during market volatilityTop Performing Stocks - Newser
What makes Harrow Inc. stock price move sharplyFree Stock Portfolio Optimization - Newser
Harrow (HROW) Stock Jumps 11.4%: Will It Continue to Soar? - Yahoo Finance
HROW’s Stock Performance: A Year of Mixed Fortunes & Market Shifts - investchronicle.com
Harrow (NASDAQ:HROW) Coverage Initiated at Cantor Fitzgerald - Defense World
Harrow Shares Soar 11.35% on Cantor Fitzgerald's Overweight Rating - AInvest
Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up - Seeking Alpha
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Harrow stock jumps on Cantor Bullish view (HROW:NASDAQ) - Seeking Alpha
Finanzdaten der Harrow Inc-Aktie (HROW)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.09%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):